Rivaroxaban for thromboprophylaxis in cancer patients | New England Journal of Medicine - MD Linx

Rivaroxaban for thromboprophylaxis in cancer patients | New England Journal of Medicine  MD Linx

Internal Medicine Article: Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer.



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more